Abstract
Myeloma bone disease MBD) is the most common and dangerous effects in patients with multiple myeloma. Bisphosphonates (BP), are the treatment of choice. But, efficacy and adverse events has not been evaluated at longer follow-up. Thus, we review our experience in a tertiary cancer center, whose received zoledronic acid (ZO): in a large number of cases (1041) and longer follow-up: 4.2 to 21.6 years (median 13.8).Skeletal event (SE) were statistically better in patients who received ZA: 52 events: 8.96%,compared to 207 (42.6) p < 0.001 in patients whose did not received ZA, independently if the patients received autologous stem cell transplant or not. But, progression free survival and overall survival did not show any benefit. Adverse events were minimal, and jaw necrosis were not observed. Thus, we considered that ZA, remain to be the best treatment of MBD, but, we confirm that ZA did not show at longer follow-up any antitumor effect.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
